Cytek Biosciences, Inc. (CTKB) Valuation — DCF & Advanced Analysis | MarketCI

Navigation

Explore Analysis Investor Relations AI Assistant Compare Screener

Help Pricing Privacy Terms

Navigation

Explore Analysis Investor Relations AI Assistant Compare Screener

Help Pricing Privacy Terms

Cytek Biosciences, Inc. (CTKB) Valuation — DCF & Advanced Analysis | MarketCI | MarketCI

CTKB

Market Closed

Cytek Biosciences, Inc.

NASDAQHealthcare Medical - Devices

682 employees

CEO: Wenbin Jiang

Founded: 2021

$5.34

+$0.00(+NaN%)

Market Cap

694.11M

Beta

1.16

52W Range

N/A

Dividend Yield

0.00%

Overview Forecasts Fundamental Market Sentiment Valuation Ownership

Comprehensive Valuation

In-depth valuation analysis including DCF scenarios and peer comparisons.

AI Insight: Cytek Biosciences is currently priced 39.4% above its PERT-weighted fair value, indicating potential overvaluation. Financial health scores highlight strong liquidity and leverage but zero profitability and efficiency, signaling operational challenges. Monte Carlo analysis shows high downside risk with all scenarios below current price, reflecting elevated investment risk.

Enhanced Football Field Analysis

Loading comprehensive valuation data...

Fetching multi-methodology valuation ranges...

Explore CTKB

Overview

Key metrics and AI-powered insights

Forecast

Price targets and earnings estimates

Fundamentals

Income, balance sheet and cash flow

Valuation

P/E, DCF and valuation multiples